接受阿扎胞苷治疗患者的感染率及危险因素 - Suppr | 超能文献

Infection Rate and Risk Factors in Patients Treated With Azacitidine.

作者信息

Orero M, Villegas C, Ortiz S, Javier K P, Costa S, Pérez P L, Roig M, Linares M

机构信息

Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.

Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain.

出版信息

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):e141-2. doi: 10.1016/j.clml.2015.07.001. Epub 2015 Jul 17.

DOI:10.1016/j.clml.2015.07.001

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Infection Rate and Risk Factors in Patients Treated With Azacitidine.接受阿扎胞苷治疗患者的感染率及危险因素

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):e141-2. doi: 10.1016/j.clml.2015.07.001. Epub 2015 Jul 17.

2

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.在高危骨髓增生异常综合征患者中，与阿扎胞苷5天疗程相比，7天疗程后的感染率更高。

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5.

3

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.不同阿扎胞苷剂量方案治疗骨髓增生异常综合征或急性髓系白血病患者的疗效和安全性。

Leuk Res. 2014 Jul;38(7):744-50. doi: 10.1016/j.leukres.2014.03.004. Epub 2014 Mar 19.

4

[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].5天阿扎胞苷治疗伴有复杂核型异常的骨髓增生异常综合征及急性髓系白血病

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019.

5

Feasibility and cost-effectiveness of at home azacitidine administration.

Med Clin (Barc). 2017 Sep 8;149(5):224-225. doi: 10.1016/j.medcli.2017.04.019. Epub 2017 Jun 10.

6

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。

Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.

7

Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.阿扎胞苷用于80岁以上急性髓系白血病或骨髓增生异常综合征患者：115例患者的报告

Br J Haematol. 2020 Aug;190(3):461-464. doi: 10.1111/bjh.16680. Epub 2020 May 11.

8

Concise drug review: azacitidine and decitabine.简明药物评论：阿扎胞苷和地西他滨。

Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13.

9

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.厄洛替尼用于阿扎胞苷治疗失败后的高危骨髓增生异常综合征和急性髓系白血病的I/II期试验。

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

10

Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.接受低强度治疗方案治疗的急性髓系白血病患者的感染：危险因素及抗生素预防的疗效。

Leuk Res. 2016 Mar;42:47-51. doi: 10.1016/j.leukres.2016.01.014. Epub 2016 Feb 1.

引用本文的文献

1

Spectrum of infections in different regimens of post-induction chemotherapy in acute myeloid leukemia (): A comparative retrospective study.急性髓系白血病诱导缓解后不同化疗方案中的感染谱（）：一项比较性回顾性研究。

Heliyon. 2024 Jan 17;10(3):e24561. doi: 10.1016/j.heliyon.2024.e24561. eCollection 2024 Feb 15.